Kalvista Pharmaceuticals (NASDAQ:KALV) Downgraded to D+ at TheStreet

Kalvista Pharmaceuticals (NASDAQ:KALV) was downgraded by investment analysts at TheStreet from a “c-” rating to a “d+” rating in a note issued to investors on Thursday, TheStreetRatingsTable reports.

KALV has been the subject of several other research reports. Needham & Company LLC boosted their price target on shares of Zuora from $27.00 to $30.00 and gave the company a “strong-buy” rating in a report on Wednesday, March 20th. BidaskClub lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research lowered shares of ExlService from a “hold” rating to a “sell” rating in a report on Wednesday. Roth Capital restated a “buy” rating on shares of Kalvista Pharmaceuticals in a report on Tuesday, May 28th. Finally, ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $29.40.

Shares of NASDAQ:KALV traded down $0.26 during trading hours on Thursday, hitting $17.31. The company’s stock had a trading volume of 95,283 shares, compared to its average volume of 228,029. Kalvista Pharmaceuticals has a 52 week low of $7.95 and a 52 week high of $34.92. The firm has a market capitalization of $298.60 million, a P/E ratio of -11.31 and a beta of 2.12. The company’s fifty day moving average is $20.59.



In other news, CEO Thomas Andrew Crockett sold 10,000 shares of Kalvista Pharmaceuticals stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $24.80, for a total value of $248,000.00. Following the transaction, the chief executive officer now owns 258,810 shares of the company’s stock, valued at approximately $6,418,488. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Edward P. Feener sold 4,000 shares of Kalvista Pharmaceuticals stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $24.92, for a total transaction of $99,680.00. Following the completion of the transaction, the insider now directly owns 100,950 shares in the company, valued at approximately $2,515,674. The disclosure for this sale can be found here. In the last ninety days, insiders sold 25,501 shares of company stock worth $645,553. Insiders own 38.40% of the company’s stock.

Several institutional investors have recently modified their holdings of KALV. Flinton Capital Management LLC purchased a new position in shares of Kalvista Pharmaceuticals in the 4th quarter worth approximately $26,000. Bank of Montreal Can grew its position in shares of Kalvista Pharmaceuticals by 28.5% in the 1st quarter. Bank of Montreal Can now owns 5,824 shares of the specialty pharmaceutical company’s stock worth $166,000 after buying an additional 1,292 shares during the last quarter. Marshall Wace North America L.P. purchased a new position in shares of Kalvista Pharmaceuticals in the 1st quarter worth approximately $175,000. Tibra Equities Europe Ltd purchased a new position in shares of Kalvista Pharmaceuticals in the 1st quarter worth approximately $727,000. Finally, Northern Trust Corp grew its position in shares of Kalvista Pharmaceuticals by 32.7% in the 4th quarter. Northern Trust Corp now owns 40,728 shares of the specialty pharmaceutical company’s stock worth $805,000 after buying an additional 10,034 shares during the last quarter. 80.64% of the stock is currently owned by hedge funds and other institutional investors.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Recommended Story: Why is the LIBOR significant?

Analyst Recommendations for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.